Affimed NV Company Profile (NASDAQ:AFMD)

About Affimed NV (NASDAQ:AFMD)

Affimed NV logoAffimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes FM13, AFM11, AFM21, AFM22, AFM24, TandAb and Trispecific Abs. It has started recruitment for Phase IIa clinical trial of AFM13 in patients with Hodgkin Lymphoma. It has initiated a Phase I clinical trial of AFM11 in patients with non-Hodgkin Lymphoma. AFM21 is in preclinical development. AFM22, which is an Epidermal Growth Factor Receptor variant III (EGFRvIII)/CD16A NK-cell TandAb is in preclinical development. AFM24 is an additional CD16A NK-cell TandAb targeting a validated solid tumor target, EGFR-wild type. It is developing Trispecific Abs for treating multiple myeloma, and CD33/CD3-specific T-cell TandAb to treat acute myeloid leukemia.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:AFMD
  • CUSIP: N/A
  • Web: www.affimed.com
Capitalization:
  • Market Cap: $103.25 million
  • Outstanding Shares: 43,938,000
Average Prices:
  • 50 Day Moving Avg: $2.28
  • 200 Day Moving Avg: $2.18
  • 52 Week Range: $1.65 - $3.82
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.47
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $7.05 million
  • Price / Sales: 14.65
  • Book Value: $1.27 per share
  • Price / Book: 1.85
Profitability:
  • EBIDTA: ($34,550,000.00)
  • Net Margins: -501.31%
  • Return on Equity: -57.35%
  • Return on Assets: -48.29%
Debt:
  • Debt-to-Equity Ratio: 0.04%
  • Current Ratio: 6.27%
  • Quick Ratio: 6.24%
Misc:
  • Average Volume: 291,740 shs.
  • Beta: 3.63
  • Short Ratio: 2.96
 

Frequently Asked Questions for Affimed NV (NASDAQ:AFMD)

What is Affimed NV's stock symbol?

Affimed NV trades on the NASDAQ under the ticker symbol "AFMD."

How were Affimed NV's earnings last quarter?

Affimed NV (NASDAQ:AFMD) announced its quarterly earnings results on Wednesday, May, 17th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.24) by $0.03. The firm earned $1.94 million during the quarter, compared to analyst estimates of $1.73 million. Affimed NV had a negative return on equity of 57.35% and a negative net margin of 501.31%. Affimed NV's quarterly revenue was up 385.0% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.25) earnings per share. View Affimed NV's Earnings History.

Where is Affimed NV's stock going? Where will Affimed NV's stock price be in 2017?

3 equities research analysts have issued 1-year price objectives for Affimed NV's stock. Their predictions range from $2.00 to $10.00. On average, they anticipate Affimed NV's share price to reach $4.83 in the next year. View Analyst Ratings for Affimed NV.

Who are some of Affimed NV's key competitors?

Who owns Affimed NV stock?

Affimed NV's stock is owned by many different of retail and institutional investors. Top institutional investors include Wellington Management Group LLP (0.00%), NEA Management Company LLC (0.00%), ORBIMED ADVISORS LLC (4.67%), Tekla Capital Management LLC (0.00%), Perceptive Advisors LLC (1.67%) and Nationwide Fund Advisors (1.10%). View Institutional Ownership Trends for Affimed NV.

Who sold Affimed NV stock? Who is selling Affimed NV stock?

Affimed NV's stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc. and Muhlenkamp & Co. Inc.. View Insider Buying and Selling for Affimed NV.

Who bought Affimed NV stock? Who is buying Affimed NV stock?

Affimed NV's stock was purchased by a variety of institutional investors in the last quarter, including NEA Management Company LLC, Wellington Management Group LLP, Tekla Capital Management LLC, Nationwide Fund Advisors and Creative Planning. View Insider Buying and Selling for Affimed NV.

How do I buy Affimed NV stock?

Shares of Affimed NV can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Affimed NV stock cost?

One share of Affimed NV stock can currently be purchased for approximately $2.35.

Analyst Ratings

Consensus Ratings for Affimed NV (NASDAQ:AFMD) (?)
Ratings Breakdown: 2 Hold Ratings, 1 Buy Rating
Consensus Rating:Hold (Score: 2.33)
Consensus Price Target: $4.83 (105.67% upside)

Analysts' Ratings History for Affimed NV (NASDAQ:AFMD)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/18/2017Oppenheimer Holdings Inc.Set Price TargetBuy$10.00LowView Rating Details
4/26/2017Jefferies Group LLCBoost Price TargetHold$2.50MediumView Rating Details
11/3/2016Leerink SwannReiterated RatingHold$2.00N/AView Rating Details
5/18/2016Wells Fargo & CoReiterated RatingBuyN/AView Rating Details
4/11/2016BMO Capital MarketsInitiated CoverageOutperform$7.00N/AView Rating Details
12/10/2015LaidlawInitiated CoverageBuy$15.00N/AView Rating Details
(Data available from 5/26/2015 forward)

Earnings

Earnings History for Affimed NV (NASDAQ:AFMD)
Earnings by Quarter for Affimed NV (NASDAQ:AFMD)
Earnings History by Quarter for Affimed NV (NASDAQ:AFMD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/17/20173/31/2017($0.24)($0.21)$1.73 million$1.94 millionViewN/AView Earnings Details
3/30/201712/31/2016($0.31)($0.17)$1.20 million$1.37 millionViewN/AView Earnings Details
11/2/2016Q316($0.26)($0.31)$2.65 million$0.94 millionViewN/AView Earnings Details
8/10/2016Q216($0.22)($0.24)$2.10 million$2.07 millionViewListenView Earnings Details
5/18/2016Q116($0.15)($0.25)$1.88 million$1.90 millionViewListenView Earnings Details
3/30/2016Q415($0.18)($0.19)$1.71 million$1.66 millionViewListenView Earnings Details
11/10/2015Q315($0.25)($0.27)$1.87 million$1.20 millionViewListenView Earnings Details
8/4/2015Q215($0.14)($0.21)$2.56 million$2.21 millionViewN/AView Earnings Details
5/21/2015Q115($0.14)($0.07)$4.75 million$2.82 millionViewListenView Earnings Details
3/25/2015Q414($0.39)($0.24)$0.89 million$0.09 millionViewN/AView Earnings Details
11/18/2014Q314($0.33)$2.69$0.89 million$2.35 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Affimed NV (NASDAQ:AFMD)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20172($0.21)($0.18)($0.20)
Q3 20173($0.22)($0.18)($0.20)
Q4 20173($0.22)($0.20)($0.21)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Affimed NV (NASDAQ:AFMD)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Affimed NV (NASDAQ:AFMD)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Affimed NV (NASDAQ:AFMD)
Latest Headlines for Affimed NV (NASDAQ:AFMD)
Source:
DateHeadline
americanbankingnews.com logoResearch Analysts Offer Predictions for Affimed NV's Q2 2017 Earnings (AFMD)
www.americanbankingnews.com - May 22 at 7:18 AM
americanbankingnews.com logoQ2 2017 EPS Estimates for Affimed NV (AFMD) Lowered by Leerink Swann
www.americanbankingnews.com - May 22 at 7:18 AM
americanbankingnews.com logoQ3 2017 EPS Estimates for Affimed NV (AFMD) Reduced by Analyst
www.americanbankingnews.com - May 22 at 7:18 AM
americanbankingnews.com logoOppenheimer Holdings Inc. Analysts Give Affimed NV (AFMD) a $10.00 Price Target
www.americanbankingnews.com - May 19 at 5:54 PM
americanbankingnews.com logoAffimed NV (AFMD) Releases Quarterly Earnings Results, Beats Expectations By $0.03 EPS
www.americanbankingnews.com - May 19 at 12:50 AM
finance.yahoo.com logoAffimed to Present Immune Cell Engager Data at ASCO Annual Meeting and EACR-AACR-SIC Special Conference
finance.yahoo.com - May 17 at 8:26 PM
finance.yahoo.com logoAffimed Announces First Quarter 2017 Financial Results and Corporate Update Conference Call
finance.yahoo.com - May 10 at 9:28 AM
americanbankingnews.com logoAffimed NV (AFMD) Earns Coverage Optimism Rating of 0.23
www.americanbankingnews.com - May 4 at 7:54 AM
americanbankingnews.com logoAffimed NV (AFMD) Downgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - May 4 at 1:04 AM
americanbankingnews.com logoAffimed NV (AFMD) Expected to Announce Quarterly Sales of $1.79 Million
www.americanbankingnews.com - May 3 at 4:38 PM
americanbankingnews.com logoAffimed NV (AFMD) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - May 3 at 12:22 AM
americanbankingnews.com logoAffimed NV (AFMD) Getting Somewhat Favorable Media Coverage, Study Shows
www.americanbankingnews.com - May 1 at 11:41 AM
americanbankingnews.com logoAffimed NV (AFMD) Expected to Announce Earnings of -$0.27 Per Share
www.americanbankingnews.com - May 1 at 10:06 AM
americanbankingnews.com logoAffimed NV (AFMD) Earning Somewhat Positive Press Coverage, Analysis Finds
www.americanbankingnews.com - April 27 at 9:34 AM
americanbankingnews.com logoAffimed NV (AFMD) Stock Rating Reaffirmed by Jefferies Group LLC
www.americanbankingnews.com - April 26 at 6:46 PM
americanbankingnews.com logoAffimed NV (AFMD) Receives Media Impact Rating of 0.56
www.americanbankingnews.com - April 24 at 12:10 PM
americanbankingnews.com logoZacks Investment Research Lowers Affimed NV (AFMD) to Hold
www.americanbankingnews.com - April 21 at 9:46 PM
americanbankingnews.com logoAffimed NV (AFMD) Earns Media Impact Score of 0.40
www.americanbankingnews.com - April 20 at 10:45 AM
americanbankingnews.com logoAffimed NV (AFMD) Upgraded by Zacks Investment Research to Buy
www.americanbankingnews.com - April 19 at 8:45 PM
americanbankingnews.com logoAffimed NV (AFMD) Earning Somewhat Positive News Coverage, Analysis Shows
www.americanbankingnews.com - April 16 at 7:31 AM
finance.yahoo.com logoAffimed NV :AFMD-US: Earnings Analysis: Q4, 2016 By the Numbers : April 6, 2017
finance.yahoo.com - April 7 at 7:07 AM
americanbankingnews.com logoShort Interest in Affimed NV (AFMD) Decreases By 7.7%
www.americanbankingnews.com - April 5 at 10:18 PM
americanbankingnews.com logoAnalysts Offer Predictions for Affimed NV's FY2021 Earnings (AFMD)
www.americanbankingnews.com - April 3 at 1:02 PM
biz.yahoo.com logoQ4 2016 Affimed NV Earnings Release - Time Not Supplied
us.rd.yahoo.com - March 30 at 3:46 PM
us.rd.yahoo.com logoAffimed Reports Financial Results for Fourth Quarter and Year End 2016
us.rd.yahoo.com - March 30 at 3:46 PM
americanbankingnews.com logoAffimed NV (AFMD) Releases Earnings Results, Beats Estimates By $0.14 EPS
www.americanbankingnews.com - March 30 at 2:39 PM
americanbankingnews.com logoAffimed NV (AFMD) Set to Announce Quarterly Earnings on Tuesday
www.americanbankingnews.com - March 27 at 1:07 AM
americanbankingnews.com logoAffimed NV (AFMD) Given "Buy" Rating at Oppenheimer Holdings Inc.
www.americanbankingnews.com - March 24 at 10:24 PM
finance.yahoo.com logoAffimed Announces Fourth Quarter and Year End 2016 Financial Results and Corporate Update Conference Call
finance.yahoo.com - March 23 at 3:34 PM
americanbankingnews.com logoAffimed NV (AFMD) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - March 23 at 1:22 PM
americanbankingnews.com logoAffimed NV (AFMD) Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - March 22 at 9:43 PM
finance.yahoo.com logoAre Options Traders Betting on a Big Move in Affimed (AFMD) Stock?
finance.yahoo.com - March 20 at 3:39 PM
finance.yahoo.com logoInnocoll Holdings (INNL) Shows Strength: Stock Up 36.6%
finance.yahoo.com - March 17 at 4:05 PM
finance.yahoo.com logoAffimed (AFMD) Shares March Higher, Can It Continue?
finance.yahoo.com - March 14 at 3:20 PM
finance.yahoo.com logoAffimed to Present at the Cowen and Company 37th Annual Health Care Conference
finance.yahoo.com - March 9 at 1:31 AM
finance.yahoo.com logoAffimed to Present Data on Immune Cell Engagers at the AACR Annual Meeting 2017
finance.yahoo.com - March 9 at 1:31 AM
finance.yahoo.com logo5:22 pm Affimed Therapeutics preclinical data for lead candidate AFM13, the preclinical programs AFM24 and AFM26, as well as data on its MHC-peptide-targeting discovery program will be presented at AACR
finance.yahoo.com - March 1 at 8:21 PM
globenewswire.com logoAffimed to Present at the Cowen and Company 37th Annual Health Care Conference - GlobeNewswire (press release)
globenewswire.com - February 28 at 8:23 AM
finance.yahoo.com logoCan The Uptrend Continue for Affimed N.V. (AFMD)?
finance.yahoo.com - February 27 at 3:32 PM
globenewswire.com logoAffimed to Present at the Leerink Partners 6th Annual Global Healthcare Conference - GlobeNewswire (press release)
www.globenewswire.com - February 8 at 3:27 PM
finance.yahoo.com logoAffimed to Present at the Leerink Partners 6th Annual Global Healthcare Conference
finance.yahoo.com - February 8 at 3:27 PM
nasdaq.com logoAffimed (AFMD) Shows Strength: Stock Moves 8.1% Higher - Nasdaq
www.nasdaq.com - February 6 at 3:25 PM
globenewswire.com logoAffimed Announces Closing of Public Offering of Common Stock ... - GlobeNewswire (press release)
www.globenewswire.com - January 26 at 3:36 PM
globenewswire.com logoAffimed Announces Closing of Public Offering of Common Stock - GlobeNewswire (press release)
globenewswire.com - January 25 at 8:33 PM
finance.yahoo.com logoAffimed Announces Closing of Public Offering of Common Stock
finance.yahoo.com - January 25 at 8:33 PM
finance.yahoo.com logoAffimed Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - January 20 at 3:28 PM
us.rd.yahoo.com logo4:04 pm Affimed Therapeutics commences an underwritten public offering of its common shares; size not disclosed
us.rd.yahoo.com - January 19 at 8:44 PM
finance.yahoo.com logoAffimed Announces Proposed Public Offering of Common Stock
finance.yahoo.com - January 19 at 8:44 PM

Social

Chart

Affimed NV (AFMD) Chart for Friday, May, 26, 2017

This page was last updated on 5/26/2017 by MarketBeat.com Staff